Trial Profile
A Randomized double-blind Phase II trial evaluating maintenance olaparib versus placebo in patients with platinum-sensitive advanced non-small cell lung cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Dec 2023
Price :
$35
*
At a glance
- Drugs Olaparib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms PIPSeN
- 14 Dec 2023 Primary endpoint has not been met, (Progression Free Survival), as per Results published in the British Journal of Cancer
- 14 Dec 2023 Results published in the British Journal of Cancer
- 08 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.